What it is
Cagrilintide is a man-made peptide (a short chain of amino acids, the building blocks of proteins). It is an 'amylin analogue', which means a modified copy of amylin. Amylin is a natural hormone made in the pancreas. The US label for pramlintide, an approved amylin analogue, says amylin is stored and released together with insulin after eating, and that it slows the emptying of the stomach, lowers the release of glucagon (a hormone that raises blood sugar) and helps control food intake through the brain's appetite centres.
More on what it is and where it came from
Pramlintide (brand name Symlin) has been approved in the United States since 2005 as an add-on to mealtime insulin for adults with diabetes. Its label gives a half-life (the time for the blood level to fall by half) of about 48 minutes. Cagrilintide was designed by Novo Nordisk to last far longer. It carries a fatty acid side chain, and in an early trial its half-life was 159 to 195 hours, about seven to eight days. In trials it was given as an injection under the skin once a week.
Cagrilintide has been studied on its own and, much more widely, combined with semaglutide. Semaglutide is an approved medicine that copies a different hormone, GLP-1. The combination is called CagriSema. Neither cagrilintide nor CagriSema was an approved medicine anywhere that we could find as of 18 November 2026. Products sold online as cagrilintide are not the trial drug and have not been checked by any regulator.
Cagrilintide was discovered and developed by the Danish drug company Novo Nordisk. Company scientists described how it was made in the Journal of Medicinal Chemistry in 2021. They wrote that natural amylin tends to clump into fibres, which makes it hard to turn into a medicine, and that pramlintide has a short half-life, and that cagrilintide was built as a stable, long-acting amylin analogue with a fatty acid attached. A first trial combining it with semaglutide began in 2018, and a 706-person trial of cagrilintide alone enrolled people in 2019; both were published in The Lancet in 2021. The phase 3 programme for CagriSema in obesity (called REDEFINE) began in November 2022 according to ClinicalTrials.gov, and its two main trials were published in the New England Journal of Medicine in 2025. A separate phase 3 programme of cagrilintide on its own (called RENEW) began in November 2025 and has not reported results.
How it is thought to work
Cagrilintide is described in the research papers as a drug that switches on amylin receptors and the closely related calcitonin receptor. A receptor is a docking point on a cell that a hormone fits into. The idea is that it copies the 'I am full' signal of natural amylin, but for days instead of minutes.
More on how it works
The detail comes from animals. In a 2025 mouse study, cagrilintide lowered body weight and food intake in normal mice, and worked less well in mice bred to lack two parts of the amylin receptor, which suggests its effect depends on those receptors. It also activated nerve cells in parts of the hindbrain. A 2026 study that mapped hindbrain cells in rats, mice and monkeys found, in rats, that cagrilintide's effect depended on one particular group of nerve cells; switching off a gene in those cells removed the effect of cagrilintide but not of semaglutide. Whether the same cells do this job in people has not been shown.
CagriSema pairs cagrilintide with semaglutide, which acts on a different receptor (GLP-1). In people, the combination produced more weight loss than either drug alone in the trials that compared them. In a 2026 rat study, about 86% of CagriSema's weight loss was explained by eating less and about 14% by the body keeping up its energy use; the same study found the rats ate more and regained weight quickly once treatment stopped.
What is established in people
For cagrilintide on its own, the published human evidence is modest: one 26-week trial in 706 people showed weight loss of 6% to 11% across dose levels against 3% on placebo, and small single-drug groups inside larger trials point the same way. For the combination with semaglutide (CagriSema), placebo-controlled phase 3 trials lasting 68 weeks in several thousand adults showed large average weight loss (about 20% without diabetes and about 14% with type 2 diabetes) and better blood sugar control, with stomach and gut side effects in most participants. It is not established whether CagriSema lowers the risk of heart attack and stroke, how safe it is beyond about a year and a half, or what happens after stopping; and in the one head-to-head trial, announced by the company, it did not match tirzepatide. Every trial cited here was paid for by Novo Nordisk, and neither cagrilintide nor CagriSema is an approved medicine.
What the studies found
12 studies, human trials first. Each links to the paper or registry record.
- Human trial2026
REDEFINE 4 (company announcement only): 'CagriSema demonstrated 23% weight loss in an open-label head-to-head REDEFINE 4 trial in people with obesity, the primary endpoint was not achieved'
COMPANY ANNOUNCEMENT, NOT PEER REVIEWED.
Full finding, who was studied, and limits
Who: 809 adults with obesity and at least one related condition, randomly assigned to CagriSema or to tirzepatide (an approved obesity medicine made by Eli Lilly) for 84 weeks. Open-label, meaning participants and doctors knew which drug was being given.
COMPANY ANNOUNCEMENT, NOT PEER REVIEWED. The trial was designed to show that CagriSema was 'non-inferior' to tirzepatide, meaning not meaningfully worse. It did not show this. Counting everyone regardless of whether they stayed on treatment, average weight loss was 20.2% on CagriSema and 23.6% on tirzepatide. In the analysis that assumes people stayed on treatment, the figures were 23.0% and 25.5%. Novo Nordisk said the most common side effects were in the stomach and gut and were mostly mild to moderate.
Read with care: Written by the company that makes CagriSema and not checked by independent reviewers. It gives no side-effect numbers for either drug. Open-label trials can be affected by people knowing what they are taking. The ClinicalTrials.gov record shows the trial as completed with no results posted (last updated 6 February 2026).
- Human trial2026
Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial
This trial's main question was whether CagriSema produces more weight loss than semaglutide alone.
Full finding, who was studied, and limits
Who: 331 adults at 21 sites in Japan and one in Taiwan, with a BMI of 27 or more plus weight-related conditions; 24% had type 2 diabetes and 68% were men. 164 were assigned to CagriSema and 167 to semaglutide alone, double-blind, for 68 weeks.
This trial's main question was whether CagriSema produces more weight loss than semaglutide alone. At 68 weeks body weight had fallen by 18.4% on CagriSema and 11.9% on semaglutide, a difference of 6.5 percentage points. Side effects were reported by 87% and 84% of the two groups; stomach and gut problems by 53% and 51%. 10% stopped CagriSema and 6% stopped semaglutide. One person in the semaglutide group died; the investigator judged the death unrelated to treatment.
Read with care: A few hundred people in two places in East Asia, mostly men. The main analysis assumes people took the treatment as intended. No placebo group. Paid for by Novo Nordisk.
- Human trial2026
Efficacy and safety of co-administered cagrilintide-semaglutide (CagriSema) [two lower dose levels] in adults with overweight or obesity (REDEFINE 9): a multicentre, randomised, double-blind within-dose-level, placebo-controlled, parallel-group, phase 3b trial
At 68 weeks body weight had fallen by 20.7% and 21.0% in the two CagriSema groups and by 2.0% on placebo, in the analysis that assumes people took the treatment as intended.
Full finding, who was studied, and limits
Who: 309 adults without diabetes who had obesity or overweight plus a related condition, at 24 sites in Canada, France, Germany, the UK and the USA. 77% were women and the average BMI was 39. They were assigned to one of two CagriSema dose levels lower than the one used in the main trials, or to placebo, for 68 weeks.
At 68 weeks body weight had fallen by 20.7% and 21.0% in the two CagriSema groups and by 2.0% on placebo, in the analysis that assumes people took the treatment as intended. About 95% of people on CagriSema lost at least 5% of their weight, compared with 33% on placebo. Side effects were reported by 99% and 95% of the CagriSema groups and 91% of the placebo group, mostly mild or moderate stomach and gut problems. No one died.
Read with care: About 100 people per group. The two lower dose levels were not compared with the standard dose in the same trial, so it does not show they work equally well. 82% were still on treatment at week 68. Paid for by Novo Nordisk. Online-ahead-of-print version; abstract only.
- Human trial2026
Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study
This is the largest CagriSema trial in type 2 diabetes that we found.
Full finding, who was studied, and limits
Who: 2,713 adults with type 2 diabetes not well controlled on metformin, with a BMI of 25 or more, in 30 countries. Six groups for 68 weeks: CagriSema at two dose levels, semaglutide at two dose levels, cagrilintide alone (152 people) and placebo (149 people).
This is the largest CagriSema trial in type 2 diabetes that we found. At 68 weeks HbA1c had fallen by 1.91 percentage points on higher-dose CagriSema and by 1.75 on the matching dose of semaglutide alone. The difference, 0.16 points, was statistically clear but small. Side effects were reported by 86.9% on higher-dose CagriSema, 81.2% on semaglutide, 82.2% on cagrilintide alone and 70.5% on placebo. The most common were in the stomach and gut.
Read with care: The extra blood sugar benefit of adding cagrilintide to semaglutide was small. The abstract gives no weight results and no results for the cagrilintide-alone group other than side effects. A correction to the paper was published in the same issue; we did not see what it changed. Paid for by Novo Nordisk.
- Human trial2026
Cagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study
At 40 weeks HbA1c had fallen by 2.33 and 2.10 percentage points in the two CagriSema groups and by 0.66 on placebo.
Full finding, who was studied, and limits
Who: 274 adults with type 2 diabetes already taking once-daily long-acting insulin, at 46 centres in six countries. Two CagriSema dose levels (90 and 93 people) or placebo (91 people) for 40 weeks.
At 40 weeks HbA1c had fallen by 2.33 and 2.10 percentage points in the two CagriSema groups and by 0.66 on placebo. Body weight fell by 10% to 12% on CagriSema. Side effects were reported by 80% and 71% of the CagriSema groups and 71% of the placebo group. No severe low blood sugar was reported. One person on CagriSema died of cancer; the report says this was not related to treatment.
Read with care: Small and 40 weeks long. Compared with placebo, not with another diabetes medicine. Paid for by Novo Nordisk. Abstract only.
The Lancet 2026;408(10549):38-51 (ClinicalTrials.gov NCT06323161) · pubmed.ncbi.nlm.nih.gov
- Human trial2025
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity
This is the largest trial with published results.
Full finding, who was studied, and limits
Who: 3,417 adults without diabetes who had obesity, or overweight plus at least one weight-related condition. Phase 3, double-blind, 68 weeks. 2,108 were assigned to CagriSema, 302 to semaglutide alone, 302 to cagrilintide alone and 705 to placebo. All groups also received lifestyle support.
This is the largest trial with published results. At 68 weeks average body weight had fallen by 20.4% on CagriSema and 3.0% on placebo, counting all participants. People on CagriSema were more likely to lose at least 5%, 20%, 25% and 30% of their weight. Stomach and gut side effects (nausea, vomiting, diarrhoea, constipation or stomach pain) affected 79.6% of the CagriSema group and 39.9% of the placebo group, and were described as mainly short-lived and mild to moderate. The journal abstract does not give the results for the two single-drug groups. A Novo Nordisk company announcement (20 December 2024, not peer reviewed) gave them as 11.5% for cagrilintide alone and 14.9% for semaglutide alone, counted the same way.
Read with care: Paid for by Novo Nordisk. Only the abstract was read. The single-drug figures quoted here come from a company announcement. The same announcement said only 57.3% of the CagriSema group were on the highest dose at week 68, and it headlined a larger figure (22.7%) that comes from an analysis assuming everyone stayed on treatment. 68 weeks is not long-term for a condition treated for life.
- Human trial2025
Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes
At 68 weeks average body weight had fallen by 13.7% on CagriSema and 3.4% on placebo.
Full finding, who was studied, and limits
Who: 1,206 adults with type 2 diabetes and a BMI of 27 or more, in 12 countries. Phase 3, double-blind, 68 weeks. 904 were assigned to CagriSema and 302 to placebo, with lifestyle support.
At 68 weeks average body weight had fallen by 13.7% on CagriSema and 3.4% on placebo. An HbA1c of 6.5% or lower (a common blood sugar target) was reached by 73.5% of the CagriSema group and 15.9% of the placebo group. Stomach and gut side effects were reported by 72.5% on CagriSema and 34.4% on placebo, most of them short-lived and mild or moderate.
Read with care: Weight loss was smaller than in people without diabetes. There was no comparison with semaglutide alone, so this trial cannot show what cagrilintide added. Paid for by Novo Nordisk. Abstract only.
- Human trial2023
Efficacy and safety of co-administered once-weekly cagrilintide [dose] with once-weekly semaglutide [dose] in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial
HbA1c (a blood test showing average blood sugar over about three months) fell by 2.2 percentage points on CagriSema, 1.8 on semaglutide and 0.9 on cagrilintide alone.
Full finding, who was studied, and limits
Who: 92 adults with type 2 diabetes and a BMI of 27 or more, already taking metformin, at 17 US sites. 31 received CagriSema, 31 semaglutide alone and 30 cagrilintide alone, for 32 weeks.
HbA1c (a blood test showing average blood sugar over about three months) fell by 2.2 percentage points on CagriSema, 1.8 on semaglutide and 0.9 on cagrilintide alone. The difference between CagriSema and semaglutide was not statistically clear. Body weight fell by 15.6% on CagriSema, 5.1% on semaglutide and 8.1% on cagrilintide alone. Side effects were reported by 68%, 71% and 80% of the three groups, mostly mild or moderate stomach and gut problems. There were no deaths and no clinically significant low blood sugar.
Read with care: About 30 people per group and 32 weeks. There was no placebo group. On blood sugar, cagrilintide alone did clearly worse than the other two groups. Paid for by Novo Nordisk.
The Lancet 2023;402(10403):720-730 (ClinicalTrials.gov NCT04982575) · pubmed.ncbi.nlm.nih.gov
- Human trial2021
Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial
This is the main published trial of cagrilintide on its own.
Full finding, who was studied, and limits
Who: 706 adults without diabetes who had obesity, or overweight plus high blood pressure or abnormal blood fats, at 57 sites in 10 countries. About 100 people were in each of five cagrilintide dose groups, 99 took liraglutide (an approved daily GLP-1 medicine) and 101 took placebo. Treatment lasted 26 weeks, with 6 more weeks of follow-up off treatment.
This is the main published trial of cagrilintide on its own. At 26 weeks average body weight had fallen by 6.0% in the lowest-dose group and by 10.8% in the highest-dose group (6.4 to 11.5 kg), compared with 3.0% (3.3 kg) on placebo. The highest dose produced slightly more weight loss than liraglutide (10.8% compared with 9.0%). Stomach and gut side effects were reported by 41% to 63% of the cagrilintide groups and 32% of the placebo group. Nausea was reported by 20% to 47% and 18%. One in ten participants stopped treatment for good, 4% because of side effects.
Read with care: Only 26 weeks long, which is short for a weight-loss treatment. Each dose group had about 100 people. The headline figures assume everyone kept taking the drug; the authors say results were similar when everyone was counted. Paid for by Novo Nordisk.
The Lancet 2021;398(10317):2160-2172 (ClinicalTrials.gov NCT03856047) · pubmed.ncbi.nlm.nih.gov
- Human trial2021
Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide [dose] for weight management: a randomised, controlled, phase 1b trial
This was the first trial of the combination later called CagriSema.
Full finding, who was studied, and limits
Who: 96 otherwise healthy adults aged 18 to 55 with a BMI of 27 to 39.9, at one US site. Six groups received rising dose levels of cagrilintide or placebo, all on top of semaglutide, for 20 weeks. 95 received treatment.
This was the first trial of the combination later called CagriSema. Its main purpose was safety. Side effects were reported by 97% of people on cagrilintide plus semaglutide and 96% of people on placebo plus semaglutide; 37% of all reported events were in the stomach and gut, and most were mild to moderate. Cagrilintide's half-life was 159 to 195 hours, and it did not change semaglutide's blood levels. At 20 weeks, weight had fallen by 15.4% to 17.1% in the three higher cagrilintide dose groups, compared with 8.0% to 9.8% on semaglutide with placebo.
Read with care: Small (about 12 people per group), short and at a single site. It was built to check safety and blood levels, not benefit. Paid for by Novo Nordisk.
The Lancet 2021;397(10286):1736-1748 (ClinicalTrials.gov NCT03600480) · pubmed.ncbi.nlm.nih.gov
- Animal study2026
Continued CagriSema treatment preserves weight loss by reducing energy intake and maintaining energy expenditure in rats
Weight loss on CagriSema came mostly from eating less (about 86% of the effect), with the rest from the body keeping up its energy use.
Full finding, who was studied, and limits
Who: Male rats made obese by diet, treated for 6 weeks and then followed for 4 weeks after treatment stopped. CagriSema was compared with no treatment and with rats whose food was restricted to match.
Weight loss on CagriSema came mostly from eating less (about 86% of the effect), with the rest from the body keeping up its energy use. When treatment stopped, the rats ate more than before and regained weight quickly. The authors wrote that long-term treatment may be needed to keep weight off.
Read with care: Rats only, male only. What happens to people after stopping CagriSema has not been reported in the papers we opened. The abstract does not state who paid for the study.
Molecular Metabolism 2026;115:102464, published online 28 October 2026 · pubmed.ncbi.nlm.nih.gov
- Animal study2025
Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3
Normal mice given cagrilintide lost weight (about 3.4 g) and ate less in the first days.
Full finding, who was studied, and limits
Who: Male mice made obese with a high-fat diet for 23 weeks, then treated for 3 weeks. Normal mice were compared with mice bred to lack two parts of the amylin receptor (RAMP1 and RAMP3). About 8 mice per group.
Normal mice given cagrilintide lost weight (about 3.4 g) and ate less in the first days. In mice lacking the two receptor parts, cagrilintide was less potent. Cagrilintide activated nerve cells in hindbrain areas involved in fullness signals, and this activation was 57% lower in one of those areas in the mice lacking the receptor parts. The authors concluded that its weight effect depends on two forms of the amylin receptor.
Read with care: Mice only, male only, small groups and three weeks. Mouse findings often do not carry over to people. Part of the funding came from Novo Nordisk, and some authors were company employees.
Safety findings
- Cagrilintide alone, 26-week phase 2 trial (706 people): stomach and gut side effects were reported by 41% to 63% of the cagrilintide groups and 32% of the placebo group. Nausea was the main one (20% to 47%, against 18% on placebo). Constipation, diarrhoea and reactions at the injection site were also frequent. 10% of participants stopped treatment for good, 4% because of side effects. Source: pubmed.ncbi.nlm.nih.gov
- CagriSema, largest trial (REDEFINE 1, 3,417 people, 68 weeks): stomach and gut side effects, including nausea, vomiting, diarrhoea, constipation or stomach pain, affected 79.6% of the CagriSema group and 39.9% of the placebo group. The authors described them as mainly short-lived and mild to moderate. Source: pubmed.ncbi.nlm.nih.gov
- COMPANY PRESS RELEASE (not peer reviewed), 18 December 2025: Novo Nordisk reported that in REDEFINE 1 nausea affected 55% of people on CagriSema and 12.6% on placebo, constipation 30.7% and 11.6%, and vomiting 26.1% and 4.1%. It said 5.9% of people on CagriSema stopped because of side effects, compared with 3.5% on placebo, and in REDEFINE 2 (people with type 2 diabetes) 8.4% compared with 3%. Source: novonordisk.com
- In people with type 2 diabetes (REDEFINE 2, 1,206 people, 68 weeks), stomach and gut side effects were reported by 72.5% on CagriSema and 34.4% on placebo. In the 2,713-person REIMAGINE 2 trial, any side effect was reported by 86.9% on higher-dose CagriSema, 82.2% on cagrilintide alone and 70.5% on placebo. Source: pubmed.ncbi.nlm.nih.gov
7 more safety findings
- Low blood sugar: the approved amylin analogue pramlintide carries a boxed warning on its US label about severe low blood sugar when it is used with mealtime insulin. In the 274-person REIMAGINE 3 trial, where CagriSema was added to once-daily long-acting insulin for 40 weeks, no severe low blood sugar was reported. That is one small trial with a different insulin type, so it does not settle the question. Source: pubmed.ncbi.nlm.nih.gov
- Heart rhythm: a dedicated study in 105 healthy volunteers (53 on cagrilintide, 52 on placebo) found no clinically relevant lengthening of the QT interval, a measurement on a heart tracing that is used to screen drugs for a risk of dangerous heart rhythms. Source: pubmed.ncbi.nlm.nih.gov
- Kidney and liver problems: two single-dose studies (33 and 32 people) found that blood levels of cagrilintide were similar in people with reduced kidney or liver function and in people with normal function. There were no serious side effects. The groups were very small (4 to 14 people each). Source: pubmed.ncbi.nlm.nih.gov
- Heart attack and stroke: not yet known. A trial designed to answer this (REDEFINE 3) randomised 7,076 adults with existing heart or blood vessel disease to CagriSema or placebo. It was still running when we checked; ClinicalTrials.gov lists its main measurements as due in September 2027, and no results have been published. Source: pubmed.ncbi.nlm.nih.gov
- Blood pressure: in an analysis of REDEFINE 1, systolic blood pressure (the top number) fell by 10.9 mmHg on CagriSema and 2.8 mmHg on placebo over 68 weeks. A fall in a risk marker is not the same as fewer heart attacks or strokes. Source: pubmed.ncbi.nlm.nih.gov
- Deaths in the trials we read: one in the semaglutide-only group of REDEFINE 5, one (from cancer) in a CagriSema group of REIMAGINE 3, and none in REDEFINE 9 or the phase 2 diabetes trial. Trial investigators judged both deaths unrelated to treatment. The abstracts of REDEFINE 1, REDEFINE 2 and REIMAGINE 2 do not report deaths or serious side effects, and we could not open the full papers. Source: pubmed.ncbi.nlm.nih.gov
- Unapproved products: the FDA states that cagrilintide is not a component of any FDA-approved drug and has not been found safe and effective for any condition. FDA warning letters dated 10 December 2024 and 31 March 2026 went to websites selling products labelled as cagrilintide 'for research use only'. We found no published study of what such products actually contain. Source: fda.gov
Rules and status
Not approved. Cagrilintide is an investigational (experimental) drug, alone and in the CagriSema combination. As of 18 November 2026 we found no approval by the FDA or by any other regulator.
The full history, with dates
APPROVAL. Novo Nordisk said in a company press release dated 18 December 2025 that it had submitted a New Drug Application to the FDA for once-weekly CagriSema for long-term weight management in adults with obesity, or with overweight and at least one weight-related condition. The same release said CagriSema was not approved in the US or the EU. In its financial report of 4 November 2026 (company announcement No 65/2026) Novo Nordisk listed the US decision as expected in the fourth quarter of 2026 and said it was preparing for a US launch in early 2027, subject to approval. These dates are the company's; we found no FDA document giving a decision date. The FDA's own list of novel drug approvals for 2026, current as of 18 November 2026, contains no entry for cagrilintide or CagriSema. The same company report said an application for CagriSema had been submitted to China's drug regulator, with the review expected to finish in the first half of 2028. We found no announcement of a filing with the European Medicines Agency (EMA), and the EMA's list of new medicines under evaluation for November 2026 (updated 17 November 2026) does not include cagrilintide. Cagrilintide on its own has not been filed anywhere that we could find; its phase 3 trials (RENEW 1 and 2) are still running, with results expected by the company in the second half of 2027. UNAPPROVED PRODUCTS AND COMPOUNDING. The FDA's public page on unapproved GLP-1 drugs (content current as of 1 October 2026) says that retatrutide and cagrilintide cannot be used in compounding under federal law, that they are not components of FDA-approved drugs, and that they have not been found safe and effective for any condition. Cagrilintide does not appear in either table on the FDA's page of bulk substances that may present significant safety risks (content current as of 22 April 2026). FDA warning letters to Xcel Research LLC (10 December 2024) and Prime Sciences (31 March 2026) named cagrilintide products, and in the first case a cagrilintide-semaglutide blend, as unapproved new drugs. In both letters the FDA said the 'research use only' and 'not for human use' labels were contradicted by the sellers' own website claims about weight loss and blood sugar. On 30 October 2026 the health department (HHS) published a draft, non-binding policy on pharmacy compounding of certain peptides (91 FR 68526). The notice text does not name any peptide. Appendix A of the policy (on hhs.gov, read from an Internet Archive capture of 15 November 2026) names exactly six peptides: BPC-157, epitalon, KPV, MOTS-c, semax and TB-500. Cagrilintide is not among them.
Source: fda.gov (source dated 2026-10-01)
In sport: Not named on the WADA Prohibited List for 2026 (in force from 1 January 2026) or 2027 (in force from 1 January 2027); neither List contains 'cagrilintide' or 'amylin'. Class S0 (Non-approved substances) prohibits at all times 'any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use (e.g. drugs under pre-clinical or clinical development ...)'. No other section names cagrilintide, and this page found no approval of it, alone or as CagriSema, by any regulator as of 18 November 2026, so S0 applies and it is prohibited at all times. The 2027 List adds 'peptides' to the S0 examples, and WADA's 2027 explanatory note says that even if a peptide is not specifically named on the List, 'it may still be prohibited'. If a regulator approves CagriSema, this would need to be re-checked. Separately, semaglutide, the other ingredient of CagriSema, is not prohibited; it is on WADA's Monitoring Program (watched, not banned) for 2026 and 2027. WADA
Claims and what the evidence supports
| What people say | What the evidence supports |
|---|---|
| Cagrilintide is the next approved weight-loss drug, so it is as good as approved already. | It is not approved. The FDA says cagrilintide has not been found safe and effective for any condition. Novo Nordisk says it applied for approval of the CagriSema combination in December 2025; an application is not an approval, and no application for cagrilintide on its own was found. Source: fda.gov |
| CagriSema is stronger than tirzepatide. | The only head-to-head trial in obesity (REDEFINE 4, 809 people, 84 weeks) failed to show that CagriSema was even as good as tirzepatide: 20.2% average weight loss compared with 23.6%, counting all participants. This comes from a company announcement and has not been published in a journal. In a separate company-reported trial in type 2 diabetes, a lower dose level of CagriSema produced more weight loss than a low dose level of tirzepatide (12.4% compared with 9.1% at 60 weeks), so the comparison depends on the dose levels chosen. Source: novonordisk.com |
| Cagrilintide on its own works as well as the GLP-1 medicines. | Not in the trial that tested both. In REDEFINE 1, the company reported 11.5% average weight loss for cagrilintide alone and 14.9% for semaglutide alone over 68 weeks (company announcement; the journal abstract does not give these figures). In the 26-week phase 2 trial, the highest cagrilintide dose gave 10.8% against 9.0% for liraglutide, an older daily GLP-1 medicine. Source: pubmed.ncbi.nlm.nih.gov |
| Amylin drugs are gentler on the stomach than GLP-1 drugs. | The trials we read do not support this. On cagrilintide alone, 41% to 63% of people had stomach and gut side effects and up to 47% had nausea, against 32% and 18% on placebo. In the phase 2 diabetes trial, side effects were reported by 80% of the cagrilintide-alone group and 71% of the semaglutide group, though the groups were too small (about 30 each) to compare reliably. Source: pubmed.ncbi.nlm.nih.gov |
| Cagrilintide sold online 'for research' is legal to buy and is the same as the trial drug. | No evidence supports either part. The trial drug is made by Novo Nordisk and supplied through clinical trials. The FDA has sent warning letters to websites selling cagrilintide under 'research use only' labels, calling the products unapproved new drugs, and says cagrilintide cannot be used in compounding. Source: fda.gov |
| The weight stays off after you stop. | We found no published human data on what happens after stopping cagrilintide or CagriSema. In a 2026 rat study, the animals ate more and regained weight quickly once CagriSema was stopped, and the authors suggested long-term treatment may be needed. A longer trial in people (REDEFINE 11, 80 weeks with an 80-week extension) is running; the company expects results in the first half of 2027. Source: pubmed.ncbi.nlm.nih.gov |
| It protects the heart. | Not shown. In an analysis of REDEFINE 1, blood pressure fell more on CagriSema than on placebo, but that is a risk marker. The trial designed to count heart attacks and strokes (REDEFINE 3, 7,076 people) has not reported. Source: pubmed.ncbi.nlm.nih.gov |
What a genuine lab report should show
- Identity by mass spectrometry: the measured mass should match cagrilintide's expected mass (average molecular weight about 4409 g/mol; monoisotopic mass about 4406.25 Da, per PubChem). A report that shows only a purity figure, with no mass result, does not prove what the substance is.
- Purity by HPLC (a method that separates a sample into its parts): the report should show the actual chromatogram trace, not just a percentage, along with the method and the date of the test.
- Blends need two answers, not one. Products sold as a cagrilintide-semaglutide mix contain two different molecules with different masses. A genuine report should identify each one separately and state the amount of each. A single purity figure for a blend is not meaningful.
- Amount per vial (peptide content), tested separately from purity. A sample can be very pure and still contain much less, or much more, than the label says.
- Traceability: a genuine report names the independent laboratory, carries a lot or batch number that matches the label, is dated, and can be confirmed with the laboratory directly.
- A lab report shows what is in one tested sample. It does not make a product an approved medicine, and it says nothing about safety in people.
What is not known
- Has the FDA decided on CagriSema? Novo Nordisk expected a decision in the fourth quarter of 2026. We found none as of 18 November 2026, and the FDA does not publish target dates, so this page could go out of date within weeks.
- Has Novo Nordisk filed in Europe? We found no announcement of an EMA filing and cagrilintide is not on the EMA's November 2026 list of medicines under evaluation, but we did not find a company statement saying when it plans to file.
- REDEFINE 4 (against tirzepatide) is known only from a company announcement. Side-effect numbers for the two drugs, and the full results, have not been published.
- How well does cagrilintide work on its own over the long term? The only completed stand-alone trial lasted 26 weeks. The RENEW 1 and RENEW 2 phase 3 trials (300 and 330 people, 64 weeks) are running, with results expected by the company in the second half of 2027.
- Heart attack and stroke risk is unknown until REDEFINE 3 reports (main measurements due September 2027 according to ClinicalTrials.gov).
- Serious side effects and deaths in REDEFINE 1, REDEFINE 2 and REIMAGINE 2 are not given in the abstracts, and we could not open the full papers. Someone with journal access should add them.
- A 2025 opinion article in The Lancet raised an untested idea that amylin-type drugs might switch on the renin-angiotensin system, a hormone system that raises blood pressure. The authors noted that blood pressure actually fell in the CagriSema trials and called for studies. No data yet.
- Only 57.3% of people on CagriSema in REDEFINE 1 were on the highest dose at week 68, according to the company. Why so many were on lower doses, and how that affected results, is not explained in the sources we opened. A later trial tested lower dose levels, and the company says a trial of a higher-dose version has started.
- What happens after stopping treatment has only been reported in rats.
- The one-letter sequence was worked out from the chemical name on PubChem and needs a chemist's check. The specific amino-acid changes that separate cagrilintide from pramlintide and from human amylin were not confirmed from a source we opened.
Sources
All 48 sources
- Phase 2 dose-finding trial of cagrilintide alone, Lancet 2021 (PubMed). pubmed.ncbi.nlm.nih.gov
- Phase 1b trial of cagrilintide with semaglutide, Lancet 2021 (PubMed). pubmed.ncbi.nlm.nih.gov
- Phase 2 CagriSema trial in type 2 diabetes, Lancet 2023 (PubMed). pubmed.ncbi.nlm.nih.gov
- REDEFINE 1 phase 3 obesity trial, NEJM 2025 (PubMed). pubmed.ncbi.nlm.nih.gov
- REDEFINE 1 registry record (NCT05567796). clinicaltrials.gov
- REDEFINE 2 phase 3 trial in obesity with type 2 diabetes, NEJM 2025 (PubMed). pubmed.ncbi.nlm.nih.gov
- Company announcement No 99/2024, REDEFINE 1 headline results, 20 December 2024 (not peer reviewed). novonordisk.com
- Company announcement No 11/2025, REDEFINE 2 headline results, 10 March 2025 (not peer reviewed). novonordisk.com
- Company announcement No 13/2026, REDEFINE 4 against tirzepatide, 23 February 2026 (not peer reviewed). novonordisk.com
- REDEFINE 4 registry record (NCT06131437). clinicaltrials.gov
- REDEFINE 5 trial in Japan and Taiwan, Lancet Diabetes Endocrinol 2026 (PubMed). pubmed.ncbi.nlm.nih.gov
- REDEFINE 9 lower-dose trial, Lancet Diabetes Endocrinol 2026 (PubMed). pubmed.ncbi.nlm.nih.gov
- REDEFINE 3 cardiovascular outcomes trial, design and baseline paper, Am Heart J 2026 (PubMed). pubmed.ncbi.nlm.nih.gov
- REDEFINE 3 registry record (NCT05669755). clinicaltrials.gov
- Blood pressure analysis of REDEFINE 1, Hypertension 2026 (PubMed). pubmed.ncbi.nlm.nih.gov
- REIMAGINE 1 trial in type 2 diabetes on diet and exercise, Lancet Diabetes Endocrinol 2026 (PubMed). pubmed.ncbi.nlm.nih.gov
- REIMAGINE 2 trial in type 2 diabetes, Lancet Diabetes Endocrinol 2026 (PubMed). pubmed.ncbi.nlm.nih.gov
- REIMAGINE 3 trial with basal insulin, Lancet 2026 (PubMed). pubmed.ncbi.nlm.nih.gov
- RENEW 1, cagrilintide alone in obesity, registry record (NCT07220642). clinicaltrials.gov
- RENEW 2, cagrilintide alone in obesity with type 2 diabetes, registry record (NCT07220759). clinicaltrials.gov
- Thorough QT study, Diabetes Obes Metab 2024 (PubMed). pubmed.ncbi.nlm.nih.gov
- Kidney and liver impairment studies, Clin Pharmacokinet 2026 (PubMed). pubmed.ncbi.nlm.nih.gov
- Development of Cagrilintide, a Long-Acting Amylin Analogue, J Med Chem 2021 (PubMed). pubmed.ncbi.nlm.nih.gov
- Mouse study of amylin receptors, EBioMedicine 2025 (PubMed). pubmed.ncbi.nlm.nih.gov
- Brainstem cell atlas and cagrilintide in rats, mice and monkeys, Nature Metabolism 2026 (PubMed). pubmed.ncbi.nlm.nih.gov
- Rat study of CagriSema and weight regain after stopping, Molecular Metabolism 2026 (PubMed). pubmed.ncbi.nlm.nih.gov
- Structure of cagrilintide bound to amylin and calcitonin receptors, Nature Communications 2025 (PubMed). pubmed.ncbi.nlm.nih.gov
- Review: long-acting amylin-related peptides, Peptides 2026 (PubMed). pubmed.ncbi.nlm.nih.gov
- Opinion article: amylin and the renin-angiotensin system, Lancet (PubMed). pubmed.ncbi.nlm.nih.gov
- FDA-approved label for Symlin (pramlintide), DailyMed, revised December 2019. dailymed.nlm.nih.gov
- Novo Nordisk press release: files for FDA approval of CagriSema, 18 December 2025 (company source). novonordisk.com
- Novo Nordisk financial report for January to September 2026, company announcement No 65/2026, 4 November 2026 (company source). ml-eu.globenewswire.com
- Novo Nordisk financial report for January to June 2026, company announcement No 48/2026, 4 August 2026 (company source). ml-eu.globenewswire.com
- FDA: Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (current as of 1 October 2026). fda.gov
- FDA: Novel Drug Approvals for 2026 (current as of 18 November 2026). fda.gov
- FDA warning letter to Xcel Research LLC, 10 December 2024. fda.gov
- FDA warning letter to Prime Sciences, 31 March 2026. fda.gov
- FDA: Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (current as of 22 April 2026). fda.gov
- HHS draft enforcement-discretion policy on compounding certain peptides, Federal Register, 30 October 2026 (91 FR 68526). govinfo.gov
- EMA: applications for new human medicines under evaluation by the CHMP (November 2026 list). ema.europa.eu
- WADA 2026 Prohibited List (in force 1 January 2026). wada-ama.org
- WADA 2027 Prohibited List, tracked-changes version. wada-ama.org
- WADA 2026 Monitoring Program. wada-ama.org
- WADA 2027 Monitoring Program. wada-ama.org
- PubChem compound record, CID 171397054. pubchem.ncbi.nlm.nih.gov
- HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (the six peptides) and Appendix B (HHS reasoning); read from an Internet Archive capture of 15 November 2026. hhs.gov
- WADA 2027 Prohibited List, published 21 September 2026, in force 1 January 2027. wada-ama.org
- WADA 2027 Prohibited List: summary of major modifications and explanatory notes (S0 and peptides). wada-ama.org
Sources last checked 2026-11-18.
This page summarises published research and public records for education. It is not medical advice and it is not a guide to using any compound. If something here is wrong or out of date, tell us and we will correct it.